871656-48-3

Upstream product

• 1001419-70-0 C₁₇H₁₈O₇S 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1001419-66-4 C₂₅H₂₆O₇S 
• 1001419-67-5 3-[(1S)-2-benzyloxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]benzoic acid 
• 136918-07-5 (2R)-1[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-propanol 
• 54915-31-0 methyl 3-(benzyloxy)-5-hydroxybenzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 871656-49-4 methyl 3-(benzyloxy)-5-(4-(methylsulfonyl)phenoxy)benzoate 
• 752242-45-8 3-hydroxy-5-(4-methanesulfonylphenoxy)benzoic acid methyl ester 
• 752242-47-0 5-((1S)-2-(tert-butyldimethylsiloxy)-1-methylethoxy)-3-(4-methanesulfonylphenoxy)benzoic acid methyl ester 

Downstream Products

• 1001419-72-2 C₂₅H₂₆O₈S 
• 1093121-27-7 C₃₄H₄₀N₂O₉S₂Si 
• 1093120-78-5 C₂₇H₂₃N₃O₇S₂ 
• 1093120-80-9 C₂₇H₂₄N₂O₉S₂ 
• 1093120-79-6 C₂₇H₂₅N₃O₈S₂ 
• 1093120-77-4 C₂₇H₂₄N₂O₉S₂ 
• 871656-50-7 3-[(1S)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethoxy]-N-[4-(methoxymethyl)-1,3-thiazol-2-yl]-5-[4-(methylsulfonyl)phenoxy]benzamide 
• 871656-47-2 3-((1S)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethoxy)-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide 

Relevant academic research and scientific papers

1, 3 - DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS

Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R1 is alkyl, aryl, arylalkyl, heteroaryl, or he

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n-Z-(CH2)m—PO(OR7)(OR8), —(CH2)nZ-(CH2)m—PO(OR7)Rg, —(CH2)n-Z-(CH2)m—OPO(OR7)Rg, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10);R5 and R6 are independently selected from H, alkyl and halogen;Y is R7(CH2)s or is absent; andX, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.